A phase I study of an oral selective gamma secretase (GS) inhibitor RO4929097 in combination with neoadjuvant paclitaxel and carboplatin in triple negative breast cancer

Upregulation of Notch pathway is associated with poor prognosis in breast cancer. We present the results of a phase I study of an oral selective gamma secretase (GS) inhibitor (critical to Notch signaling), RO4929097 in combination with neoadjuvant chemotherapy for operable triple negative breast ca...

Volledige beschrijving

Bewaard in:
Bibliografische gegevens
Gepubliceerd in:Invest New Drugs
Hoofdauteurs: Sardesai, Sagar, Badawi, Mohamed, Mrozek, Ewa, Morgan, Evan, Phelps, Mitch, Stephens, Julie, Wei, Lai, Kassem, Mahmoud, Ling, Yonghua, Lustberg, Maryam, Stover, Daniel, Williams, Nicole, Layman, Rachel, Reinbolt, Raquel, VanDeusen, Jeffrey, Cherian, Mathew, Grever, Michael, Carson, William, Ramaswamy, Bhuvaneswari, Wesolowski, Robert
Formaat: Artigo
Taal:Inglês
Gepubliceerd in: 2020
Onderwerpen:
Article
Online toegang:https://ncbi.nlm.nih.gov/pmc/articles/PMC7955776/
https://ncbi.nlm.nih.gov/pubmed/31953695
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s10637-020-00895-5
Tags: Voeg label toe
Geen labels, Wees de eerste die dit record labelt!

Gelijkaardige items